Frequency and Distribution of the Clinical Presentation of Oral Candidiasis in Immunocompromised Patients with Candida and Non-Candida Genus Species
Immunocompromised patients with symptoms compatible with mycoses in the oral mucosa can be caused by different etiological agents regardless of their clinical presentation or systemic disease. Yeast fungi have been described as disease markers for some specific diseases. That is why there is a tende...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Artículo revista |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2022
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/39096 |
| Aporte de: |
| id |
I10-R327-article-39096 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| format |
Artículo revista |
| topic |
Oral Candidiasis Immunocompromised Candida Candidiasis Oral Inmunocomprometidos Candida . |
| spellingShingle |
Oral Candidiasis Immunocompromised Candida Candidiasis Oral Inmunocomprometidos Candida . Baggio , G Duarte , M Carballo, GM Gay Stabile, RL Valfre, R Juri, G Frequency and Distribution of the Clinical Presentation of Oral Candidiasis in Immunocompromised Patients with Candida and Non-Candida Genus Species |
| topic_facet |
Oral Candidiasis Immunocompromised Candida Candidiasis Oral Inmunocomprometidos Candida . |
| author |
Baggio , G Duarte , M Carballo, GM Gay Stabile, RL Valfre, R Juri, G |
| author_facet |
Baggio , G Duarte , M Carballo, GM Gay Stabile, RL Valfre, R Juri, G |
| author_sort |
Baggio , G |
| title |
Frequency and Distribution of the Clinical Presentation of Oral Candidiasis in Immunocompromised Patients with Candida and Non-Candida Genus Species |
| title_short |
Frequency and Distribution of the Clinical Presentation of Oral Candidiasis in Immunocompromised Patients with Candida and Non-Candida Genus Species |
| title_full |
Frequency and Distribution of the Clinical Presentation of Oral Candidiasis in Immunocompromised Patients with Candida and Non-Candida Genus Species |
| title_fullStr |
Frequency and Distribution of the Clinical Presentation of Oral Candidiasis in Immunocompromised Patients with Candida and Non-Candida Genus Species |
| title_full_unstemmed |
Frequency and Distribution of the Clinical Presentation of Oral Candidiasis in Immunocompromised Patients with Candida and Non-Candida Genus Species |
| title_sort |
frequency and distribution of the clinical presentation of oral candidiasis in immunocompromised patients with candida and non-candida genus species |
| description |
Immunocompromised patients with symptoms compatible with mycoses in the oral mucosa can be caused by different etiological agents regardless of their clinical presentation or systemic disease. Yeast fungi have been described as disease markers for some specific diseases. That is why there is a tendency to carry out empirical treatments (Fluconazole) for oral mycosis, however these treatments are not always the best prescription or effective, due to ignorance of the strain or gender of the fungi. Thus, it’s always recommended to start with a phenotypic identification of the infection and complement it with a sensibilization test. The objectives of this study were to determine the distribution of Candida and Non-Candida species in immunocompromised patients with clinical symptoms of oral candidiasis.
For this, 145 patients with symptoms of oral candidiasis and immunocompromised, from different services of the Clínicas National Hospital of Córdoba, were selected over 16 pre-pandemic months. They were swabbed to confirm the disease mycologically. With the material obtained, the algorithm for isolation and phenotypic identification of yeasts was followed.
Of the 145, 127 patients presented clinically and mycologically confirmed oral candidiasis with the phenotypic march for yeast identification, the following species were isolated and identified: 1) Candida yeasts: (52%) C.albicans, (13%) C.tropicalis, (9%) C.glabrata, (7%) C.parapsilosis, (6%) C.dubliniensis, (5%) C. krussei, (2%) C.guilliermondii, (2%) C.kefyr, (1%) C.intermedia, C.lusitaniae, (1%) C.norvegensis, (1%) C.pararugosa; and 2) Non-Candida Yeasts: (1%) Trichosporon spp, (1%) Saccharomyces cerevisiae. There were n=150 samples of the 127 patients, unique (83%) and associated (17%).
With this we can conclude that the identification of species is essential when determining the appropriate treatment for the immunocompromised patient, since not all these yeasts are Candida species, so they may not be sensitive to commonly used azole antifungals. We then propose the identification of the yeasts, by means of an algorithm based on safe phenotypic methods and to carry out antifungal sensitivity tests in the presence of emerging species, little sensitive, or resistant to commonly used antifungals. |
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2022 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/39096 |
| work_keys_str_mv |
AT baggiog frequencyanddistributionoftheclinicalpresentationoforalcandidiasisinimmunocompromisedpatientswithcandidaandnoncandidagenusspecies AT duartem frequencyanddistributionoftheclinicalpresentationoforalcandidiasisinimmunocompromisedpatientswithcandidaandnoncandidagenusspecies AT carballogm frequencyanddistributionoftheclinicalpresentationoforalcandidiasisinimmunocompromisedpatientswithcandidaandnoncandidagenusspecies AT gaystabilerl frequencyanddistributionoftheclinicalpresentationoforalcandidiasisinimmunocompromisedpatientswithcandidaandnoncandidagenusspecies AT valfrer frequencyanddistributionoftheclinicalpresentationoforalcandidiasisinimmunocompromisedpatientswithcandidaandnoncandidagenusspecies AT jurig frequencyanddistributionoftheclinicalpresentationoforalcandidiasisinimmunocompromisedpatientswithcandidaandnoncandidagenusspecies AT baggiog frecuenciaydistribuciondelapresentacionclinicadecandidiasisoralenpacientesinmunocomprometidosconespeciesdelgenerocandidaynocandida AT duartem frecuenciaydistribuciondelapresentacionclinicadecandidiasisoralenpacientesinmunocomprometidosconespeciesdelgenerocandidaynocandida AT carballogm frecuenciaydistribuciondelapresentacionclinicadecandidiasisoralenpacientesinmunocomprometidosconespeciesdelgenerocandidaynocandida AT gaystabilerl frecuenciaydistribuciondelapresentacionclinicadecandidiasisoralenpacientesinmunocomprometidosconespeciesdelgenerocandidaynocandida AT valfrer frecuenciaydistribuciondelapresentacionclinicadecandidiasisoralenpacientesinmunocomprometidosconespeciesdelgenerocandidaynocandida AT jurig frecuenciaydistribuciondelapresentacionclinicadecandidiasisoralenpacientesinmunocomprometidosconespeciesdelgenerocandidaynocandida |
| first_indexed |
2024-09-03T21:04:12Z |
| last_indexed |
2024-09-03T21:04:12Z |
| _version_ |
1809210359086579712 |
| spelling |
I10-R327-article-390962024-04-15T16:14:45Z Frequency and Distribution of the Clinical Presentation of Oral Candidiasis in Immunocompromised Patients with Candida and Non-Candida Genus Species Frecuencia y Distribución de la Presentación Clínica de Candidiasis Oral en pacientes Inmunocomprometidos con especies del género Candida y no Candida . Baggio , G Duarte , M Carballo, GM Gay Stabile, RL Valfre, R Juri, G Oral Candidiasis Immunocompromised Candida Candidiasis Oral Inmunocomprometidos Candida . Immunocompromised patients with symptoms compatible with mycoses in the oral mucosa can be caused by different etiological agents regardless of their clinical presentation or systemic disease. Yeast fungi have been described as disease markers for some specific diseases. That is why there is a tendency to carry out empirical treatments (Fluconazole) for oral mycosis, however these treatments are not always the best prescription or effective, due to ignorance of the strain or gender of the fungi. Thus, it’s always recommended to start with a phenotypic identification of the infection and complement it with a sensibilization test. The objectives of this study were to determine the distribution of Candida and Non-Candida species in immunocompromised patients with clinical symptoms of oral candidiasis. For this, 145 patients with symptoms of oral candidiasis and immunocompromised, from different services of the Clínicas National Hospital of Córdoba, were selected over 16 pre-pandemic months. They were swabbed to confirm the disease mycologically. With the material obtained, the algorithm for isolation and phenotypic identification of yeasts was followed. Of the 145, 127 patients presented clinically and mycologically confirmed oral candidiasis with the phenotypic march for yeast identification, the following species were isolated and identified: 1) Candida yeasts: (52%) C.albicans, (13%) C.tropicalis, (9%) C.glabrata, (7%) C.parapsilosis, (6%) C.dubliniensis, (5%) C. krussei, (2%) C.guilliermondii, (2%) C.kefyr, (1%) C.intermedia, C.lusitaniae, (1%) C.norvegensis, (1%) C.pararugosa; and 2) Non-Candida Yeasts: (1%) Trichosporon spp, (1%) Saccharomyces cerevisiae. There were n=150 samples of the 127 patients, unique (83%) and associated (17%). With this we can conclude that the identification of species is essential when determining the appropriate treatment for the immunocompromised patient, since not all these yeasts are Candida species, so they may not be sensitive to commonly used azole antifungals. We then propose the identification of the yeasts, by means of an algorithm based on safe phenotypic methods and to carry out antifungal sensitivity tests in the presence of emerging species, little sensitive, or resistant to commonly used antifungals. Los pacientes inmunocomprometidos con clínica compatible con micosis en mucosa oral pueden ser causadas por diferentes agentes etiológicos independientemente de su presentación clínica o enfermedad sistémica. Se ha descrito a los hongos levaduriformes como causa de enfermedad marcadora de algunas enfermedades específicas. Es por ello que se tiende a realizar tratamientos empíricos (Ej Fluconazol) para estas micosis orales, sin embargo estos tratamientos no son siempre los más indicados o eficaces, debido al desconocimiento de la cepa o del género. Es por ello que se recomienda siempre comenzar con una identificación fenotípica del agente en cuestión y complementar con una prueba de sensibilización. Los objetivos de este estudio fueron conocer la distribución de especies Candida y No-Candida en pacientes inmunocomprometidos con clínica de candidiasis oral. Para ello se seleccionaron 145 pacientes con clínica de candidiasis oral e inmunocomprometidos, provenientes de distintos servicios del HNC de Córdoba, a lo largo de 16 meses prepandémia. Fueron hisopados, para confirmar micológicamente la enfermedad. Con el material obtenido se siguió el algoritmo para aislamiento e identificación fenotípica de levaduras. De los 145, 127 pacientes presentaron candidiasis oral confirmada clínica y micológicamente con la marcha fenotípica para identificación de levaduras, se aislaron e identificaron especies: 1) Levaduras Candida: (52%) C.albicans, (13%) C.tropicalis, (9%) C.glabrata, (7%) C.parapsilosis, (6%) C.dubliniensis, (5%) C.krussei, (2%) C.guilliermondii, (2%) C.kefyr, (1%) C.intermedia, C.lusitaniae, (1%) C.norvegensis, (1%) C.pararugosa; y 2) Levaduras No-Candida: (1%) Trichosporon spp, (1%) Saccharomyces cerevisiae. Hubo aislamientos n=150 de los 127 pacientes, únicos (83%) y asociados (17%). Con esto podemos concluir que la identificación de especies es fundamental, a la hora de determinar el tratamiento adecuado para el paciente inmunocomprometido, ya que no todas estas levaduras son especies Candida, por lo que pueden no ser sensibles a los antifúngicos azoles de uso habitual. Proponemos entonces la identificación de las levaduras, mediante algoritmo basado en métodos fenotípicos seguros y realizar pruebas de sensibilidad antifúngica ante la presencia de especies emergentes, poco sensibles, o resistentes a los antifúngicos de uso habitual. . Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2022-10-26 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion texto texto . https://revistas.unc.edu.ar/index.php/med/article/view/39096 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 79 No. Suplemento JIC XXIII (2022): Suplemento JIC XXIII Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 79 Núm. Suplemento JIC XXIII (2022): Suplemento JIC XXIII Revista da Faculdade de Ciências Médicas de Córdoba; v. 79 n. Suplemento JIC XXIII (2022): Suplemento JIC XXIII 1853-0605 0014-6722 http://creativecommons.org/licenses/by-nc/4.0 |